High Flow Nasal Cannula in Children With Status Asthmaticus

Status Asthmaticus Clinical Trial

— CANULASTHM  

Official title:

High Flow Nasal Cannula Versus Standard Oxygen Therapy in Children With Status Asthmaticus: a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03157102
• Other study ID #: 69HCL17_0035
• Secondary ID: IDRCB
• Status: Completed
• Phase: N/A
• Start date: August 8, 2018
• Est. completion date: June 29, 2023

Study information

• Verified date: September 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In France, over 2.5 million people suffer from asthma, including one-third of children. This is the chronic respiratory disease leading to the highest rate of hospitalization. The conventional oxygen delivery means in children are the non-rebreather face mask or low flow nasal cannula (standard oxygen therapy - SOT). New non-invasive ventilatory support systems such as High Flow Nasal Cannula (HFNC) are emerging. These are nasal cannulas allowing the delivery of a high air (or oxygen) flow, exceeding the inspiratory flow of patients with acute respiratory failure, allowing to deliver a slight positive expiratory pressure while ensuring humidification and warming of the airways. Aerosol administration is also possible with excellent efficiency and without interrupting respiratory assistance. Physiological data and clinical studies in other pathologies suggest the interest of this technique during the asthma attack, but no comparative study currently exists in this indication. The HFNCs could have their place upstream of Non Invasive Ventilation (NIV), thus replacing non-rebreather face mask sometimes not tolerated by the children. The investigators's hypothesis is that HFNCs could improve patients' health faster, reduce the use of other ventilatory assistance (NIV, invasive ventilation) and reduce the duration of hospitalization in intensive care units or continuous monitoring units (CMU).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 272
• Est. completion date: June 29, 2023
• Est. primary completion date: June 29, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 17 Years

Eligibility

Inclusion Criteria:

• Age = 6 months and <18 years old

• Hospitalized in PICU with status asthmaticus defined by

1. a PRAM score > 7 with no response at H2 to the conventional treatment according to the GINA (Global Initiative for Asthma guidelines) protocol: Oxygen therapy, Continuous nebulization of beta2 agonist for at least one hour then every hour, Oral or intravenous corticosteroid (ie methylprednisolone 2mg/kg/j)

2. or with hypercapnic acidosis (pCO2 > 45 mmHg and pH < 7,35)

• Informed consent signed by at least on parent or legal guardians prior to inclusion and oral consent of the other parent if absent

Exclusion Criteria:

• Non-corrected congenital heart disease, or neuromuscular disease, or chronic respiratory disease (pulmonary or bronchial fibrosis, cystic fibrosis), or ENA disease (laryngo or tracheo malacia), scoliosis or chronic metabolic disease

• Need for non-invasive or invasive ventilation (Glasgow comas scale <8, hemodynamic instability, refractory hypoxemia, cardiac arrest)

• Pneumothorax confirmed on the X-ray

• No national health coverage

Related Conditions & MeSH terms

• Status Asthmaticus

Intervention

Device:
• HFNC
Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%. All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). .
• Standard Oxygen Treatment
Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group. All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion.

Locations

Country	Name	City	State
France	Hôpital Femme-Mère-Enfant	Bron
France	CHU de Dijon	Dijon
France	CHU de Grenoble Alpes	Grenoble
France	Hôpital Bicêtre	Le Kremlin Bicêtre
France	Hôpital Timone 2	Marseille
France	CH Annecy Genevois	Metz-Tessy
France	CHU Arnaud de Villeneuve	Montpellier
France	CHU de Nantes	Nantes
France	Chu Lenval	Nice
France	Hôpital Armand Trousseau	Paris
France	Hôpital Necker Enfants Malades	Paris
France	Hôpital Robert Debré	Paris
France	CHU Strasbourg,	Strasbourg,
France	CH Villefranche sur Saône,	Villefranche sur Saône

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with first line treatment Failure as defined below in the first 24 hours	First line treatment Failure in the first 24 hours is defined as: Occurrence or worsening of hypercapnic acidosis (pH<7.35 with pCO2>45 mmHg); Or worsening of PRAM score (>=2 from baseline); Or SpO2<92% with maximal flow of oxygen depending on age in the group standard oxygen therapy or with FiO2 > 60% associated with a flow between 1 and 3L/Kg/min in the HFNC group; Or occurrence or worsening of the level of consciousness with Glasgow coma scale < 12; Or the need of invasive or noninvasive ventilation (Glasgow coma scale<8, hemodynamic instability, refractory hypoxemia) at any time during the first 24 hours	up to hour 24
Secondary	Number of Patients requiring noninvasive ventilation (NIV)		month 1
Secondary	Number of Patients requiring invasive ventilation (IV).		month 1
Secondary	Duration of invasive ventilation (IV).	Duration in hours	month 1
Secondary	Duration of noninvasive ventilation (NIV)	Duration in hours	month 1
Secondary	Comfort assessed by the FLACC score		up to hour 24
Secondary	Duration of supplemental oxygen therapy (in hours)		month 1
Secondary	Time from inclusion to restoration of a PRAM score < 8 (in hours).		month 1
Secondary	Time from inclusion to blood gas normalization (pCO2<45 mmHg and pH>7.35) if available (hours)		month 1
Secondary	Cumulative dose of treatments (salbutamol, corticosteroid magnesium sulfate)	in milligram during PICU stay	month 1
Secondary	total number of hours of PICU stay		month 1